{
  "docId": "019de514-ccd3-748d-b023-c1d4dfac77d9",
  "docSlug": "25647a28d2c930a2587d7a5892ea41b6",
  "documentTitle": "Bausch+Lomb | Investor Conference Presentation Deck | 25 slides",
  "authorId": "bausch-lomb",
  "authorName": "Bausch+Lomb",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 25,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "propose_solution",
  "function": "propose_solution",
  "density": "overcrowded",
  "nDataPoints": 10,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de514-ccd3-748d-b023-c1d4dfac77d9/18",
  "deckHref": "/decks/019de514-ccd3-748d-b023-c1d4dfac77d9",
  "deckJsonHref": "/decks/019de514-ccd3-748d-b023-c1d4dfac77d9.json",
  "deckAnchorHref": "/decks/019de514-ccd3-748d-b023-c1d4dfac77d9#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.27,
        "w": 0.38,
        "x": 0.54,
        "y": 0.63
      },
      "kind": "chart",
      "text": "Ocular Dryness² (ITT³)\nN=311 -45.4%\nN=309 -29.8%\np<0.001\nNOV03₁ Saline",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "82457f19-b44e-4a68-bbde-2af0c73a9fbc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.27,
        "w": 0.38,
        "x": 0.102,
        "y": 0.63
      },
      "kind": "chart",
      "text": "Total Corneal Staining² (ITT³)\nN=311 -33.3%\nN=309 -15.8%\np<0.001\nNOV03₁ Saline",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea1ddb10-f2a6-41de-9588-8e5c5a0b4e21",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.016,
        "w": 0.287,
        "x": 0.639,
        "y": 0.277
      },
      "kind": "list",
      "text": "U.S. Prescription Dry Eye Market Growth",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c9d531c1-ec46-44fd-baf6-c6697adc1a85",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.09,
        "x": 0.83,
        "y": 0.37
      },
      "kind": "metric",
      "text": "Expect Double Digit Growth\n2021-2027⁵,⁶",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2e5a6a3b-e26d-4d1f-b365-f2be69ad2091",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.08,
        "x": 0.67,
        "y": 0.37
      },
      "kind": "metric",
      "text": "~24% CAGR\n2016-2021⁴",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a68962a5-1311-4db4-a904-32e4ce6ec2e9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.046,
        "w": 0.44,
        "x": 0.133,
        "y": 0.343
      },
      "kind": "paragraph",
      "text": "Consistent statistically significant efficacy, safety and tolerability have now been demonstrated in two Phase 3 studies of NOV03¹ and one Phase 2 study",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6deb8b5c-81bf-47d6-a4d7-9ac6e540da4f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.046,
        "w": 0.44,
        "x": 0.133,
        "y": 0.421
      },
      "kind": "paragraph",
      "text": "Statistically significant difference of sign and symptom was noted at day 15 and 57 in both Phase 3 studies",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d52cdbf1-6c09-4b79-8ebf-89700b1243a6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.601,
        "x": 0.325,
        "y": 0.525
      },
      "kind": "paragraph",
      "text": "Second Phase 3 (MOJAVE) Efficacy Endpoints:\nTotal Corneal Staining (sign) and Ocular Dryness (symptom) at Day 57",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e27a5230-6066-4179-998f-790a15a3acb4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.036,
        "w": 0.44,
        "x": 0.133,
        "y": 0.265
      },
      "kind": "paragraph",
      "text": "Investigational first in class treatment for Dry Eye Disease (DED) associated with Meibomian Gland Dysfunction (MGD)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fbd2bc3e-12f4-4234-9f11-8311530bad63",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.602,
        "x": 0.158,
        "y": 0.927
      },
      "kind": "source-note",
      "text": "1. In 2019, the Company acquired an exclusive license from Novaliq GmbH for the commercialization and development of NOV03 in the United States and Canada.\n2. P-value for the difference in Least Squared Means.\n3. Intent-to-treat.\n4. IQVIA NSP.\n5. Clarivate\n6. See Slide 1 for further information on forward-looking statements.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0556d552-465f-4c79-9184-cb74424281c3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.029,
        "w": 0.8,
        "x": 0.1,
        "y": 0.18
      },
      "kind": "title",
      "text": "Pivotal Phase 3 trial GOBI Data on NOV03 Now Published in Ophthalmology",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fb0630bc-7569-40fa-84f2-0341417bc425",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.429,
        "x": 0.044,
        "y": 0.08
      },
      "kind": "title",
      "text": "NOV03¹: PDUFA Date June 2023",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "596b9d39-8ae0-4eaf-9bc3-2cb229c0fd0d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Action Titles",
      "slug": "action-titles",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "f62e3920-e520-42ac-9fd7-48efbe513ea1",
      "evidence": "The slide has a title/action-title: Pivotal Phase 3 trial GOBI Data on NOV03 Now Published in Ophthalmology",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 21,
      "from": 14,
      "beatId": "79a6f329-2f71-4631-9aa9-bf36730ec9aa",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The deck presents solutions to withstand macro economic challenges and grow",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}